source
- FDA holds hearing on access and safety as psychedelic drug approval loomsThe Food and Drug Administration convened a public hearing to collect input on how emerging psychedelic medicines should be used, monitored, and continuously studied as a potential first approval a…
- Corbus reports phase 1b obesity data showing lower neuropsychiatric side effects for CB1 antagonistCorbus Pharmaceuticals released results from a phase 1b trial of its CB1 inverse agonist aimed at treating obesity. The study indicated the drug lowered rates of depression, anxiety, irritability a…